Evidence map›Paper›PMID 41158983›Full record

ArticleDrug design, development and therapy2025

Chronic Inflammatory Comprehensive Signature Predicts Oxaliplatin and 5-Fluorouracil Benefit in Early Colorectal Cancer.

Yue Peng, Rong Shang, Zhi-Jie Wang, Qiu-Ying Ye, Xiao-Yan Tang, Xue-Xin Cheng, Hou-Qun Ying

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue PengJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Rong ShangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Zhi-Jie WangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Qiu-Ying YeDepartment of Medical Technology, Jiangxi Medical College, Shangrao, Jiangxi, People's Republic of China.
Xiao-Yan TangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Xue-Xin ChengJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Hou-Qun YingJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.ORCID 0000-0003-3858-4761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Precision delivery of adjuvant chemotherapy (ACT) improves healthcare efficiency and postoperative quality of life in stage II-III colorectal cancer (CRC). However, there remains an unmet need for identifying biomarkers that can predict therapeutic responses to 5-fluorouracil (5-FU) and oxaliplatin. Methods: We analyzed three independent cohorts (1676 stage II-III surgical cases) to evaluate the prognostic role of 12 inflammatory indices. A novel Chronic Inflammatory Comprehensive Signature (CICS) was developed using multivariable Cox regression. Three-year recurrence-free survival (RFS) and overall survival (OS) were compared between CICS-stratified subgroups (CICS-L vs CICS-H) receiving 5-FU- or oxaliplatin-based ACT. Results: Two novel inflammatory ratios (FPSIIR, FPSIRIR) and six composite scores (FPSIIS, FPSIRIS, FPSIRS, FASIIS, FASIRS, FASIRIS) independently predicted prognosis across all three cohorts (all Conclusion: CICS-quantified cancer-derived inflammation inversely correlates with the therapeutic responsiveness to 5-FU/oxaliplatin. A CICS-guided strategy maximizes survival outcomes while precision-deescalating chemotherapy use without compromising outcomes, establishing a biomarker-driven paradigm for personalized postoperative management of CRC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsFluorouracilInflammationOxaliplatinAgedBiomarkers, TumorCohort StudiesFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorFluorouracilOxaliplatin5-fluorouracilCEA-CA19-9-CICS scorechronic inflammatory comprehensive signaturecolorectal canceroxaliplatin

Identifiers

PMID41158983
PMCPMC12558162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.